China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center.
- Кому может быть актуально
- Состояния в реестре: Type1diabetes, Diabetes. Базовые параметры: Без ограничений · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Китай
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset \<= 20 years. CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.
Подробное описание
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study to investigate the demographic characteristics, metabolic control, complications occurrence as well as risk factors of patients with T1D, and to investigate the clinical features, complications' burdens and risk factors in pediatric adolescent patients with diabetes who had an age of onset \<= 20 years.
Вмешательства
- Другое Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Первичные конечные точки
- Change in serum hemoglobin A1c level [Срок оценки: Every year for up to 10 years]
- Albumin-to-creatinine ratio in urine sample [Срок оценки: up to 10 years]
- Arteriosclerotic cardiovascular diseases [Срок оценки: up to 10 years]
- Electromyography [Срок оценки: up to 10 years]
- PHQ-9 [Срок оценки: up to 10 years]
- GAD-7 [Срок оценки: up to 10 years]
- WHO-5 [Срок оценки: up to 10 years]
- PAID [Срок оценки: up to 10 years]
Вторичные конечные точки (7)
- Change in C-peptide [Срок оценки: Every year for up to 10 years]
- Change in titer of autoantibodies [Срок оценки: Every year for up to 10 years]
- Fasting blood glucose [Срок оценки: Every year for up to 10 years]
- Systolic blood pressure [Срок оценки: Every year for up to 10 years]
- Diastolic blood pressure [Срок оценки: Every year for up to 10 years]
- Change in lipid profiles [Срок оценки: Every year for up to 10 years]
- Metabolomics [Срок оценки: Every year for up to 10 years]
Критерии участия
Критерии включения
- 1\. Patients with type 1 diabetes mellitus of any duration; meeting criteria (1) or any of (2) or any of (3)
- Clinical diagnosis of type 1 diabetes by a specialist
- Age at onset < 15 years; no overweight or obesity at onset; previous diabetic ketoacidosis; highest random C-peptide < 200 pmol/L
- Initiation and continuation of insulin therapy (except pancreatic or islet transplantation) after diagnosis; positive islet autoantibodies Or 2. Children and adolescents with diabetes mellitus at age of onset <= 20 years, regardless of type and duration of disease.
Критерии исключения
- For enrolment of patients with T1D, exclusion was made if any of the following criteria were met (not applicable to those with onset under 20 years of age)
- No insulin dependence for at least 6 months after diagnosis of diabetes mellitus.
- No DKA for 1 month off insulin for those with a history of diabetes > 1 year. ③ C-peptide > 800 pmol/L at any time point.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Другое
Центры проведения
Китай · 11 центров
- Gansu Provincial People's Hospital — Lanzhou
- Shenzhen Second People's Hospital — Шэньчжэнь
- Hainan General Hospital — Haikou
- the First Affiliated Hospital of Harbin Medical University — Харбин
- The First Affiliated Hospital of Henan University of Science and Technology — Luoyang
- The Second Xiangya Hospital, Central South University — Чанша
- The First Affiliated Hospital of Nanjing Medical University — Нанкин
- Heji Hospital Affiliated to Changzhi Medical College — Changzhi
- … и ещё 3 центра
Публикации
- Deng C, Fan W, Xie Y, Tang X, Jiang H, Niu X, Yan D, Su H, Kuang H, Tian L, Liu J, Jiang S, Quan H, Xu J, Wu X, Tao N, Sun S, Li J, Guo R, Chen Y, He B, Fan L, Cao C, Huang F, Huang G, Zhou Z, Li X; CD1S Study Group. Health Inequities in Older Adults With Type 1 Diabetes: A Nationwide Registry Analysis of Sociodemographic and Clinical Profiles for Glycaemic Control and Complications. Diabetes Obes PMID 42152598
Идентификаторы
NCT: NCT05498974 · CD1S